<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the implications of erythroblasts <z:chebi fb="0" ids="29149">periodic acid</z:chebi>-Schiff (<z:chebi fb="61" ids="27565">PAS</z:chebi>) stain for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) dyserythropoiesis, diagnosis and differential diagnosis </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: <z:chebi fb="61" ids="27565">PAS</z:chebi> stain of bone marrow (BM) erythroblasts in 406 MDS patients, 207 non-severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (NSAA), 144 immune thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>), 67 <z:hpo ids='HP_0001889'>megaloblastic anemia</z:hpo> (MegA), 76 <z:hpo ids='HP_0001891'>iron deficiency anemia</z:hpo> (IDA), 50 <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>), and 50 <z:hpo ids='HP_0011009'>acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (AEL) as well as some related laboratory parameters in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were analyzed retrospectively </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: <z:chebi fb="61" ids="27565">PAS</z:chebi>-positive detection rate was significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (53.0%) than in NSAA (14.5%), <z:chebi fb="0" ids="16039">ITP</z:chebi> (27.1%) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> (16.0%), but was significantly lower in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> than in AEL (84.0%) (<z:hpo ids='HP_0000001'>all</z:hpo> P = 0.000) </plain></SENT>
<SENT sid="3" pm="."><plain>There was no significant difference in <z:chebi fb="61" ids="27565">PAS</z:chebi>-positive detection between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and MegA (46.3%), or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and IDA (40.8%) (P = 0.310, 0.052, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>Erythroblasts <z:chebi fb="61" ids="27565">PAS</z:chebi>-positive rate (Median, M = 1%) and <z:chebi fb="61" ids="27565">PAS</z:chebi>-positive scores (M' = 2) was significantly lower in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> than in AEL (M = 8%; M' = 17), and significantly higher than in NSAA (M = 0%; M' = 0), <z:chebi fb="0" ids="16039">ITP</z:chebi> (M = 0%; M' = 0), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> (M = 0%; M' = 0), MegA (M = 0%; M' = 0), and IDA (M = 0%; M' = 0) (<z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The cut-off value of <z:chebi fb="61" ids="27565">PAS</z:chebi>-positive rate and score for distinguishing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from the other groups except AEL were 0.5% and 0.5, with a sensitivity and specificity of 60.8% and 74.4%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>For <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, the percentage of BM erythroid cells was significantly higher in <z:chebi fb="61" ids="27565">PAS</z:chebi>-positive group than in <z:chebi fb="61" ids="27565">PAS</z:chebi>-negative group (P &lt; 0.05), and so were megakaryocyte count, lymphocyte-like micromegakaryocytes count and percentage of micromegakaryocyte (P = 0.002, 0.000, 0.000, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>HGB, MCV, MCH and MCHC were significantly lower in <z:chebi fb="61" ids="27565">PAS</z:chebi>-positive group (<z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.05), and so was the neutrophil alkaling phosphatase (NALP) (P = 0.000) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="61" ids="27565">PAS</z:chebi>-positive detection rate, positive rate and score were higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with abnormal karyotype than with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype, and were also higher in IPSS high/intermediate-risk 2 group than in low/intermidiate-risk 1 group </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The positive reaction of erythroblasts <z:chebi fb="61" ids="27565">PAS</z:chebi> stain is an indicator of dyserythropoiesis </plain></SENT>
<SENT sid="10" pm="."><plain>It is helpful to the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>